COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,845 Articles (22,553 medRxiv, 8,292 bioRxiv)

Most recent first Previous |  Page 1230: Articles 12291-12300  | Next

Colloidal aggregators in biochemical SARS-CoV-2 repurposing screens
O'Donnell, H. R., Tummino, T. A., Bardine, C., Craik, C. S., Shoichet, B. K.
10.1101/2021.08.31.458413 — Posted: 2021-08-31
Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor
Capraz, T., Kienzl, N. F., Laurent, E., Perthold, J. W., Foederl-Hoebenreich, E., Gruenwald-Gruber, C., Maresch, D., Monteil, V., Niederhoefer, J., Wirnsberger, G., Mirazimi, A., Zatloukal, K., Mach, L., Penninger, J. M., Oostenbrink, C., Stadlmann, J.
10.1101/2021.08.31.458325 — Posted: 2021-08-31
Increasing incidence of parosmia and phantosmia in patients recovering from COVID-19 smell loss
Ohla, K., Veldhuizen, M. G., Green, T., Hannum, M. E., Bakke, A. J., Moein, S., Tognetti, A., Postma, E. M., Pellegrino, R., Hwang, L.-D., Albayay, J., Koyama, S., Nolden, A., Thomas-Danguin, T., Mucignat-Caretta, C., Menger, N. S., Croijmans, I., Ozturk, L., Yanik, H., Pierron, D., Pereda-Loth, V., Nunez-Parra, A., Martinez Pineda, A. M., Gillespie, D., Farruggia, M. C., Cecchetto, C., Philpott, C., Voznessenskaya, V., Cooper, K., Rohlfs Dominguez, P., Calcinoni, O., de Groot, J., Boesveldt, S., Bhutani, S., Weir, E. M., Exten, C., Joseph, P. V., Parma, V., Hayes, J. E., Niv, M. Y.
10.1101/2021.08.28.21262763 — Posted: 2021-08-31
Correlation between times to SARS-CoV-2 symptom onset and secondary transmission undermines epidemic control efforts
Linton, N. M., Akhmetzhanov, A. R., Nishiura, H.
10.1101/2021.08.29.21262512 — Posted: 2021-08-31
BNT162b2 vaccine booster dose protection: A nationwide study from Israel
Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., Mizrahi, B., Alroy-Preis, S., Ash, N., Milo, R., Huppert, A.
10.1101/2021.08.27.21262679 — Posted: 2021-08-31 Discussion: Onsite
Discrepancies in the detection of SARS-CoV-2 by qRT-PCR are dependent on the target gene used for its amplification: Implications in the diagnosis of clinical infection
Campos Pardos, E., Calvet Seral, J., Aguilera, A., Milagro Beamonte, A., Martinez Sapina, A., Barbeito, G., Perez del Molino, M. L., Gonzalo-Asensio, J.
10.1101/2021.08.30.21262536 — Posted: 2021-08-31
AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans
Loo, Y.-M., McTamney, P. M., Arends, R. H., Gasser, R. A., Abram, M. E., Aksyuk, A., Diallo, S., Flores, D. J., Kelly, E. J., Ren, K., Roque, R., Rosenthal, K., Streicher, K., Tuffy, K. M., Bond, N. J., Cornwell, O., Bouquet, J., Cheng, L. I., Dunyak, J., Huang, Y., Rosenbaum, A. I., Andersen, H., Carnahan, R. H., Crowe, J. E., Kuehne, A. I., Herbert, A. S., Dye, J. M., Bright, H., Kallewaard, N. L., Pangalos, M. N., Esser, M. T.
10.1101/2021.08.30.21262666 — Posted: 2021-08-31
The impact of pausing the Oxford-AstraZeneca COVID-19 vaccine on uptake in Europe: a difference-in-differences analysis
Jain, V., Lorgelly, P.
10.1101/2021.08.30.21262821 — Posted: 2021-08-31
The emergence of SARS-CoV-2 variants of concern is driven by acceleration of the evolutionary rate
Tay, J. H., Porter, A. F., Wirth, W., Duchene, S.
10.1101/2021.08.29.21262799 — Posted: 2021-08-31 Discussion: Onsite
Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three doses of the BNT162b2 Vaccine
Patalon, T., Gazit, S., Pitzer, V. E., Prunas, O., Warren, J. L., Weinberger, D. M.
10.1101/2021.08.29.21262792 — Posted: 2021-08-31

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).